About efgartigimod alfa
Neonatal Fc receptor blocker
Used for
- Treats generalized myasthenia gravis in adults who test positive for acetylcholine receptor antibodies.
Usual adult dose
Intravenous infusion once weekly for four weeks; dose is based on body weight.
Common side effects
- Respiratory or urinary tract infections
- Headache
- Infusion-related reactions
- Low white blood cell count
Important warnings
- May increase infection risk; assess for active infections before treatment.
- Vaccinations may be less effective; avoid live vaccines during treatment.
- Monitor for allergic reactions during and after infusion.
- May reduce levels of some medicines, including certain immunoglobulin products.
Pregnancy
There are limited human data. Use during pregnancy only when clearly needed; effects on the fetus are uncertain.
Breastfeeding
It is unknown whether efgartigimod alfa passes into breast milk; effects on infants are unknown.
Interactions
- May lower blood levels of medicines that bind to FcRn, including immunoglobulin products.
- May reduce effectiveness of some monoclonal antibody medicines.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.